0636: Serum Soluble Mediator Signatures of Lupus Nephritis Histological Features and Response to Treatment

Andrea Fava¹, Carla J. Guthridge², Joseph Kheir², Catriona Wagner³, Michelle Petri⁴, Jill Buyon⁵, Betty Diamond⁶, the Accelerating Medicines Partnership (AMP) RA/SLE⁷, Joel Guthridge² and Judith James², ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma, ⁴Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Multiple Insitutions

Background/Purpose: There is a pressing need to identify novel therapeutic approaches and noninvasive biomarkers in lupus nephritis (LN). In this study, we quantified serum soluble mediators in the large Accelerating Medicines Partnership (AMP) LN longitudinal cohort to identify novel biomarkers of histological features and treatment response and provide insights into the pathogenesis of LN.

Methods: SLE patients meeting ACR or SLICC criteria (n=268) undergoing a clinically indicated kidney biopsy with a urine protein/creatinine (UPCR) ≥0.5 were recruited for this study as part of the AMP. Serum samples were collected from patients at the time of diagnostic kidney biopsy and 3-, 6-, and 12-months post-biopsy and from 22 healthy donors (HD). Concentrations of 51 analytes, including cytokines, chemokines, and TNFR superfamily members, were analyzed by xMAP multiplex assays on the Bio-Rad BioPlex200® array system. TACE levels were determined by ELISA. Clinical response was determined at 12-months post-biopsy using the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study definitions in patients with a baseline UPCR >1.0 and International Society of Nephrology/Renal Pathology Society class III, IV, V, or combination thereof.

Results: LN patients demonstrated heterogeneity in serum soluble mediator concentrations (Fig 1). Most soluble mediators were elevated in LN patients compared to HD (Fig. 2A). Within LN, patients with proliferative LN (class III +/- V or class IV +/-V) displayed a distinct signature (Fig 2B). In particular, patients with pure proliferative LN (class III or IV) had higher serum levels of immune mediators, such as IFNβ and IL-1β, compared to nonproliferative LN (Fig 2C), including pure membranous (class V) LN (Fig 2D). In addition, several serum immune mediators correlated with intrarenal LN activity (NIH activity index), with syndecan-1 (CD138) and TNF-RII exhibiting the highest correlation (Fig 3A). In contrast, stem cell factor (SCF) and TNF-RI had the highest correlation with the chronicity index (Fig 2B). In proliferative LN, the concentrations of many immune mediators declined in treatment responders (not shown). For example, syndecan-1 and TNF-RII decreased in complete and partial responders but not in nonresponders (Fig 3C-D). In contrast, SCF levels remained relatively stable regardless of response status (Fig 3E).

Conclusion: Distinct histological features of LN are paralleled by specific signatures of circulating soluble mediators. Within LN, proliferative LN is associated with higher circulating levels of inflammatory cytokines, notably, type 1 IFNs. Furthermore, a decline in the titers of several immune mediators correlated with LN activity was associated with treatment response, suggesting a possible role in LN pathogenesis. These signatures and trajectories provide insight into LN pathogenesis, heterogeneity, and biomarker development.
Figure 1. Soluble mediator heterogeneity in lupus nephritis (LN) patients. Heatmap of the soluble mediator concentrations in healthy donors (HD) and LN patients. International Society of Nephrology/Renal Pathology Society (ISN) class and proliferative versus non-proliferative LN are indicated by bars on the top of the heatmap.

Figure 2. Soluble mediator profiles of lupus nephritis (LN) and proliferative LN. Volcano plots demonstrating the differential abundance of soluble mediators in (A) healthy donors and LN, (B) non-proliferative (class I, II, V, or VI) and any proliferative (class III +/- V or class IV +/- V) (C) non-proliferative (class I, II, V, or VI) and pure proliferative (class III or IV), and (D) pure membranous (class V) and pure proliferative.

<img src=https://www.abstractscorecard.com/uploads/Tasks/upload/17574/QHOPTGBB-1290007-3-ANY.jpg width=440 height=398.244028405423 border=0 style=border-style: none;>
Disclosures: A. Fava, Sanofi; C. Guthridge, None; J. Kheir, None; C. Wagner, None; M. Petri, Exagen, AstraZeneca, Alexion, Amgen, AnaptysBio, Argenx, Aurinia, Biogen, Caribou Biosciences, CVS Health, EMD Serono, Eli Lilly, Emergent Biosolutions, GlaxoSmithKline (GSK), IQVIA, Janssen, Kira Pharmaceuticals, MedShr, Sanofi, SinoMab, Thermofisher, BPR Scientific Advisory Committee; J. Buyon, None; B. Diamond, None; t. (AMP) RA/SLE, None; J. Guthridge, None; J. James, Bristol-Myers Squibb(BMS), AstraZeneca, Novartis, Progentec Biosciences.